{"title":"Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes Mellitus.","authors":"Mayra Betancourt Ponce, Bridget E Shields","doi":"10.12788/cutis.1148","DOIUrl":null,"url":null,"abstract":"<p><p>Type 2 diabetes mellitus (T2DM) is a chronic disease with a rising prevalence worldwide that is characterized by hyperglycemia and insulin resistance. Metformin, which improves blood glucose levels and insulin sensitivity, is considered the first-line therapy for T2DM. In patients with T2DM who are overweight or obese, glucagonlike peptide 1 (GLP-1) and dual GLP-1/gastric inhibitory peptide (GIP) agonists are used as adjunct or alternative therapies given their dual benefits for insulin sensitivity and weight loss. Beyond the metabolic implications of T2DM medications, these agents also have hormonal and immunologic effects that may impact dermatologic diseases (eg, psoriasis, hidradenitis suppurativa [HS]). In this review, we highlight the dermatologic adverse effects and potential therapeutic benefits of metformin as well as GLP-1 and GLP-1/GIP agonists.</p>","PeriodicalId":11195,"journal":{"name":"Cutis","volume":"115 1","pages":"7-13"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cutis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12788/cutis.1148","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Type 2 diabetes mellitus (T2DM) is a chronic disease with a rising prevalence worldwide that is characterized by hyperglycemia and insulin resistance. Metformin, which improves blood glucose levels and insulin sensitivity, is considered the first-line therapy for T2DM. In patients with T2DM who are overweight or obese, glucagonlike peptide 1 (GLP-1) and dual GLP-1/gastric inhibitory peptide (GIP) agonists are used as adjunct or alternative therapies given their dual benefits for insulin sensitivity and weight loss. Beyond the metabolic implications of T2DM medications, these agents also have hormonal and immunologic effects that may impact dermatologic diseases (eg, psoriasis, hidradenitis suppurativa [HS]). In this review, we highlight the dermatologic adverse effects and potential therapeutic benefits of metformin as well as GLP-1 and GLP-1/GIP agonists.
期刊介绍：
Published since 1965, Cutis is a peer-reviewed clinical journal for the dermatologist, allergist, and general practitioner. The journal is published monthly and focuses on concise clinical articles that present the practical side of dermatology. Referenced in Index Medicus/MEDLINE, it is respected and enjoyed by both specialists and derm-active generalists, enabling its readers to get what they need quickly and efficiently. Furthermore, Cutis is read by more physicians actively involved in the day-to-day treatment of dermatologic conditions than any other dermatology publication. Covering a broad range of pertinent and timely topics, Cutis is written and edited by industry leaders. For information on article submissions, please see our Information for Authors.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
